chr11-64810109-T-G
Position:
Variant summary
Our verdict is Pathogenic. Variant got 18 ACMG points: 18P and 0B. PVS1PS1_ModeratePP5_Very_Strong
The NM_001370259.2(MEN1):āc.1A>Cā(p.Met1?) variant causes a start lost change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Pathogenic (ā ā ).
Frequency
Genomes: not found (cov: 28)
Exomes š: 0.00024 ( 0 hom. )
Failed GnomAD Quality Control
Consequence
MEN1
NM_001370259.2 start_lost
NM_001370259.2 start_lost
Scores
7
5
4
Clinical Significance
Conservation
PhyloP100: 4.25
Genes affected
MEN1 (HGNC:7010): (menin 1) This gene encodes menin, a tumor suppressor associated with a syndrome known as multiple endocrine neoplasia type 1. Menin is a scaffold protein that functions in histone modification and epigenetic gene regulation. It is thought to regulate several pathways and processes by altering chromatin structure through the modification of histones. [provided by RefSeq, May 2019]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 18 ACMG points.
PVS1
Start lost variant, no new inframe start found.
PS1
Another start lost variant in NM_001370259.2 (MEN1) was described as [Pathogenic] in Lovd
PP5
Variant 11-64810109-T-G is Pathogenic according to our data. Variant chr11-64810109-T-G is described in ClinVar as [Pathogenic]. Clinvar id is 850884.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MEN1 | NM_001370259.2 | c.1A>C | p.Met1? | start_lost | 2/10 | ENST00000450708.7 | NP_001357188.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
MEN1 | ENST00000450708.7 | c.1A>C | p.Met1? | start_lost | 2/10 | 5 | NM_001370259.2 | ENSP00000394933 | P3 |
Frequencies
GnomAD3 genomes Cov.: 28
GnomAD3 genomes
Cov.:
28
GnomAD4 exome Data not reliable, filtered out with message: AS_VQSR AF: 0.000242 AC: 243AN: 1005232Hom.: 0 Cov.: 36 AF XY: 0.000279 AC XY: 135AN XY: 484064
GnomAD4 exome
Data not reliable, filtered out with message: AS_VQSR
AF:
AC:
243
AN:
1005232
Hom.:
Cov.:
36
AF XY:
AC XY:
135
AN XY:
484064
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 28
GnomAD4 genome
Cov.:
28
Alfa
AF:
Hom.:
ClinVar
Significance: Pathogenic
Submissions summary: Pathogenic:2
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Multiple endocrine neoplasia, type 1 Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Oct 02, 2021 | For these reasons, this variant has been classified as Pathogenic. Disruption of the initiator codon has been observed in individuals with multiple endocrine neoplasia, type 1 (PMID: 28736585, 29036195; Invitae; UMD). This variant is not present in population databases (ExAC no frequency). This sequence change affects the initiator methionine of the MEN1 mRNA. The next in-frame methionine is located at codon 228. - |
Hereditary cancer-predisposing syndrome Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jul 07, 2023 | The p.M1? pathogenic mutation (also known as c.1A>C) is located in coding exon 1 of the MEN1 gene and results from a A to C substitution at nucleotide position 1. This alters the methionine residue at the initiation codon (ATG). Different substitutions impacting the same initiation codon (c.1A>G, c.1A>T, c.2T>C and c.2T>G) have been detected in individuals with features or clinical diagnoses of multiple endocrine neoplasia type 1 and familial isolated hyperparathyroidism (Ambry internal data; Villablanca A et al. Eur. J. Endocrinol. 2002 Sep;147(3):313-22; Klein RD et al. Genet. Med. 2005 Feb;7(2):131-8; Ventura M et al. Arch Endocrinol Metab, 2019 Sep;63:516-523; Romanet P et al. J Clin Endocrinol Metab, 2019 03;104:753-764). Sequence variations that modify the initiation codon are expected to result in either loss of translation initiation, N-terminal truncation, or cause a shift in the mRNA reading frame. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Uncertain
DANN
Benign
DEOGEN2
Benign
T;.;.;.;.;T;T;T;T;T;.;T;.;.
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Uncertain
D
LIST_S2
Uncertain
D;D;.;.;D;.;.;D;.;D;D;D;.;D
M_CAP
Pathogenic
D
MetaRNN
Pathogenic
D;D;D;D;D;D;D;D;D;D;D;D;D;D
MetaSVM
Pathogenic
D
MutationTaster
Benign
D;D;D;D;D;D;D;D;D;D
PROVEAN
Benign
N;N;N;N;N;N;N;N;N;N;N;N;N;N
REVEL
Pathogenic
Sift
Uncertain
D;D;D;D;D;D;D;D;D;D;T;T;T;T
Sift4G
Pathogenic
D;D;D;D;D;D;D;D;D;.;D;D;.;.
Polyphen
0.65, 0.70
.;P;P;P;P;P;P;P;P;.;.;.;.;.
Vest4
MutPred
Loss of helix (P = 0.028);Loss of helix (P = 0.028);Loss of helix (P = 0.028);Loss of helix (P = 0.028);Loss of helix (P = 0.028);Loss of helix (P = 0.028);Loss of helix (P = 0.028);Loss of helix (P = 0.028);Loss of helix (P = 0.028);Loss of helix (P = 0.028);Loss of helix (P = 0.028);Loss of helix (P = 0.028);Loss of helix (P = 0.028);Loss of helix (P = 0.028);
MVP
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at